A January 7, 2026 McMaster University news release also on EurekAlert announced a promising approach to fungal infections, Note: Links have been removed,

Fungal infections kill millions of people each year, and modern medicine is struggling to keep up. But researchers at McMaster University have identified a molecule that may help turn the tide — butyrolactol A, a chemical compound that targets a deadly, disease-causing fungi called Cryptococcus neoformans. 

Infections caused by Cryptococcus are extremely dangerous. The pathogen, which can cause pneuomia-like symptoms, is notoriously drug-resistant, and it often preys on people with weakened immune systems, like cancer patients or those living with HIV. And the same can be said about other fungal pathogens, like Candida auris or Aspergillus fumigatus — both of which, like Cryptococcus, have been declared priority pathogens by the World Health Organization.  

Despite the threat, though, doctors have only three treatment options for fungal infections.  

The gold standard is a drug class called amphotericin — though Gerry Wright, a professor in McMaster’s Department of Biochemistry and Biomedical Sciences, jokes that it’s often called “amphoterrible,” because of the major toxic side-effects that it has on humans.  

“Fungal cells are a lot like human cells, so the drugs that hurt them tend to hurt us too,” he says. “That’s why there are so few options available to patients.”  

The other two antifungal drug classes that are available — azoles and echinocandins — are much less effective treatment options, especially against Cryptococcus. Wright says azoles merely stop fungi from growing rather than outright killing them, while Cryptococcus and other fungi have become totally resistant to echinocandins, rendering them completely ineffective.  

So, with a stagnant antifungal drug pipeline, a limited arsenal of approved medicines, and rising rates of drug resistance, scientists are now betting on something called “adjuvants” as a solution to the growing health threat.  

“Adjuvants are helper molecules that don’t actually kill pathogens like drugs do, but instead make them extremely susceptible to existing medicine,” explains Wright, a member of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR). 

Looking for adjuvants that might better sensitize Cryptococcus to existing antifungal drugs, Wright’s lab screened McMaster’s vast chemical collection for candidate molecules.  

Quickly, his team found a hit: butyrolactol A, a known-but-previously understudied molecule produced by certain Streptomyces bacteria. The researchers found that the molecule could synergize with echinocandin drugs to kill fungi that the drugs alone could not.

But they had no idea how it worked — and almost didn’t bother to find out.

“This molecule was first discovered in the early 1990s, and nobody has ever really looked at it since,” Wright says. “So, when it showed up in our screens, my first instinct was to walk away from it. I thought, ‘it’s a known compound, it kind of looks like amphotericin, it’s just another toxic molecule — not worth our time.’”

But he credits the determination of postdoctoral fellow Xuefei Chen for changing his mind.

“Early on, this molecule’s activity appeared to be quite good,” says Chen, who works in Wright’s lab. “I felt that if there was even a small chance that it could revive an entire class of antifungal medicine, we had to explore it.”

After years of what Wright calls “painstaking sleuthing and detective work” led by Chen, the research team revealed exactly how the adjuvant worked.

Chen discovered that butyrolactol A acts as a plug that clogs up an important protein complex that’s “mission critical” for Cryptococcus — “when it’s jammed, all hell breaks loose,” Wright says. This disturbance renders the fungus completely vulnerable to the drugs that it once resisted.

Working with researchers in the laboratory of McMaster Professor Brian Coombes, also a member of the IIDR, the research team has since shown that butyrolactol A also functions similarly in Candida auris, which gives it broad clinical potential.  

Wright says the findings, published recently in the prestigious journal Cell, are more than a decade in the making.  

“That first screen that put butyrolactol A on our radar took place in 2014,” he notes. “More than eleven years later, thanks almost entirely to Chen, we have identified a legitimate drug candidate and an entirely new target to attack with other new drugs.”  

The discovery marks the second antifungal compound and the third new antimicrobial found by Wright’s lab in the past year.  

Here’s a citation for and a link to the paper,

Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi by
Xuefei Chen, H. Diessel Duan, Michael J. Hoy, Kalinka Koteva, Michaela Spitzer, Allison K. Guitor, Emily Puumala, Aline A. Fiebig, Guanggan Hu, Bonnie Yiu, Sommer Chou, Zhuyun Bian, Yeseul Choi, Amelia Bing Ya Guo, Wenliang Wang, Sheng Sun, Nicole Robbins, Anna Floyd Averette, Michael A. Cook, Ray Truant, Lesley T. MacNeil, Eric D. Brown, James W. Kronstad, Brian K. Coombes, Leah E. Cowen, Joseph Heitman, Huilin Li, Gerard D. Wright. Cell Volume 189, Issue 2 p620-639.e28 January 22, 2026 DOI: 10.1016/j.cell.2025.11.036 Published online: December 31, 2025

This paper is behind a paywall.